FDA approves Oralair, the first sublingual allergen extract for the treatment of pollen allergies.

EDQM has launched a database, Know-X, which collates reports on counterfeit/falsified medical products that have been detected in Council of Europe member states.

Evzio, the first naloxone treatment specifically designed to administered to opioid overdose patients by family members or caregivers, approved in 15 weeks.

More media options open publishing opportunities for drug development experts.

Carolina Medical Products changes its name to CMP Pharma to reflect current business trends.

GSK recalls alli weight loss products in the US and Puerto Rico.

The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.

FDA has announced Fresenius Kabi USA, LLC of Lake Zurich, Ill., will temporarily distribute normal saline in the United States from its Norway manufacturing facility.

Covance adds workspace and scientists to biologics team in Indianapolis facility.

RCA opens a new office in Warsaw, Poland.

AmerisourceBergen to establish a joint venture for specialty distribution with Profarma.

Baxter announces plans to split into two independent companies by mid-2015.

Pfizer intends to submit a biologics license application for its investigational Meningococcal B vaccine candidate, Bivalent rlp2086, to FDA by mid-2014.

Catalent increases its minority investment in Redwood Bioscience for engineering ADCs.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.

Adocia has reported positive results for the first clinical trial of its combination insulin formulation of fast- and long-acting insulin in patients with type I diabetes. Results showed that BioChaperone Combo provided both short- and long-term control of blood glucose in type I diabetic patients, with a faster onset and a longer duration of action.

Novartis has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

Aesica has successfully completed the validation of its high capacity manufacturing facility in Queenborough, UK, for commercial production. The

The Pediatric Praziquantel Consortium has been awarded a research grant from the Japanese Global Health Innovative Technology (GHIT) Fund. The grant will be used to fund the Consortium's clinical development program of a newly developed praziquantel pediatric formulation targeted for use in very young children, including infants and toddlers, infected with schistosomiasis.

Looking to improve patient access to new medicines, EMA creates a pilot project to explore an adaptive licensing approach with real medicines in development.

Charles River Laboratories to acquire CROs Argenta and BioFocus.

FDA approves Eliquis (apixaban) for DVT and PE in patients who have undergone hip or knee replacement surgery.

New injection-delivery systems with multiple closure points pose challenges for container closure integrity testing.

Catalent will recognize 80 years of softgel advancements with presentations at INTERPHEX.

Walker Barrier Systems builds eight mobile clean rooms for the Texas A&M Center for Innovation in Advanced Development and Manufacturing.

FDA clarifies recommendations for injectable drug products packaged in vials and ampules.

Almac expands technical, project, and operational resources in Asia.

To gain insights into the current trends of the biotechnology sector in the United Kingdom, Pharmaceutical Technology Europe spoke with Steve Bates, chief executive officer of the BioIndustry Association (BIA), the trade association for biotech companies in the UK.